Ziftomenib

Small molecule

Also known as KO-562

Approvedregulatory verdict

Evidence outlook

Approved: Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

Also in development:Acute Lymphoblastic Leukemia · Phase 1/2

Company guidance: topline data expected in 2028 (Kura Oncology, Inc., 10 Nov 2026). “o Initial topline results from the frontline KOMET-017 registrational program are anticipated in 2028, representing a key milestone in evaluating the potential to expand ziftomenib into newly diagnosed AML.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Acute Myeloid Leukemia
Phase 2 (2)
Acute Myeloid Leukemia
NCT07623616 · Kyowa Kirin Co., Ltd.
2026-04-23 – 2028-12 · Acute Myeloid Leukemia (AML)
What this study did
NCT06930352 · Uma Borate
2027-01-15 – 2028-01-31 · Acute Myeloid Leukemia
What this study did
Phase 1/2 (2)
Acute Lymphoblastic Leukemia
NCT05848687 · Tanja Andrea Gruber
2023-11-03 – 2033-12 · Lymphoblastic Leukemia
What this study did
Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 (11)
Acute Myeloid Leukemia
NCT06448013 · M.D. Anderson Cancer Center
2025-03-07 – 2030-12-31 · Acute Myeloid Leukemia
What this study did
NCT06769490 · M.D. Anderson Cancer Center
2025-07-10 – 2030-09-15 · Acute Myeloid Leukemia
What this study did
NCT05735184 · Kura Oncology, Inc.
2023-07-18 – 2030-04 · Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
What this study did
NCT06440135 · Massachusetts General Hospital
2024-06-11 – 2029-04-01 · Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, NPM1 Mutation, KMT2A Rearrangement
What this study did
NCT07411586 · M.D. Anderson Cancer Center
2026-05-28 – 2029-01-14 · Acute Myeloid Leukemia
What this study did
Relapsed/Refractory Acute Myeloid Leukemia
NCT07929740 · Kura Oncology, Inc.
2026-10-30 – 2029-02-28 · Myelodysplastic Syndrome (MDS)/AML, Myeloid Leukemia, Acute
What this study did
NCT07355335 · Massachusetts General Hospital
2026-09-02 – 2028-01-01 · KMT2A-rearranged, NPM1-mutant Refractory or Relapsed AML
What this study did
NCT06001788 · Kura Oncology, Inc.
2024-02-22 – 2027-08 · AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
What this study did
Other / comorbidity
NCT06376162 · PedAL BCU, LLC
2025-03-18 – 2033-03 · Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia
What this study did
NCT06397027 · M.D. Anderson Cancer Center
2024-12-27 – 2030-12-31 · Refractory Acute Leukemia, Pediatric Relapsed
What this study did
NCT06655246 · Kura Oncology, Inc.
2025-03-27 – 2030-06 · Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant, Gastrointestinal Stromal Cell Tumors
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Acute Lymphoblastic Leukemia: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ziftomenib: this drugPhase 1/2Small moleculeMeninnot yet gradedNo reviewed efficacy summary in this indication
BlinatumomabApprovedMultispecific antibodyCD19 x CD3Weak signal
NCT03476239: Percentage of Participants With a Hematological Response of Complete Remission (CR) or Complete Remission With Partial Hematological Recovery (CRh*) During the First 2 Treatment Cycles With Blinatumomab (Within 2 cycles of treatment (12 weeks)): Blinatumomab — Interim Analysis: 45.6 percentage of participants (95% CI 35 to 56.4); Final Analysis: 48.3 percentage of participants (95% CI 39.1 to 57.6)
MethotrexateApprovedSmall moleculeDihydrofolate reductase (DHFR), Folate Analog Metabolic Inhibitornot yet gradedNo reviewed efficacy summary in this indication
Obecabtagene Autoleucel (Aucatzyl)ApprovedCell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
Ponatinib (ICLUSIG)ApprovedSmall moleculeBCR-ABL (including T315I)Partial signalFeatured results are non-efficacy only in this race
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Icovamenib
Phase 2(overall)
Small moleculeMenin
Partial signal(overall)
No reviewed efficacy summary in this indication

Upcoming events

(16 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ziftomenib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12 · NCT06001788 · CT.gov ↗
What to watch
2027 (4)
January 2027 (1)
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-01-14 · NCT07411586 · CT.gov ↗
What to watch
March 2027 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-03 · NCT07623616 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-04-01 · NCT06440135 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-07-01 · NCT07355335 · CT.gov ↗
What to watch
2028 (6)
January 2028 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01-31 · NCT06930352 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-09-15 · NCT06769490 · CT.gov ↗
What to watch
October 2028 (1)
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-10-16 · NCT04067336 · CT.gov ↗
What to watch
December 2028 (3)
Phase 1/2Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2028-12 · NCT05848687 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT06448013 · CT.gov ↗
What to watch
Phase 1Refractory Acute Leukemia, Pediatric RelapsedRecruiting
Est. primary completion 2028-12-31 · NCT06397027 · CT.gov ↗
What to watch
2029 (2)
February 2029 (1)
Phase 1Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-02-28 · NCT07929740 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor …Recruiting
Est. primary completion 2029-06 · NCT06655246 · CT.gov ↗
What to watch
2030 (1)
April 2030 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-04 · NCT05735184 · CT.gov ↗
What to watch
2031 (1)
November 2031 (1)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2031-11 · NCT07007312 · CT.gov ↗
What to watch
2033 (1)
March 2033 (1)
Phase 1Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute LeukemiaRecruiting
Est. primary completion 2033-03 · NCT06376162 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 November 2025ApprovalFDA Boxed Warning on Ziftomenib (NDA220305)
US, FDA · FDA · Source ↗